Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Magnus1
I will do it.
Since the complaint by a board member about our idea of NANO CLUB, I have on my "HUB" page this warning written in bold and red letters and framed in red :
NOTICE: Due to a high number of Terms of Service ("TOS") violations, an Administrative Warning has been placed on this board.
Please review the warning prior to posting. Users who post in violation of the TOS will have their posts removed and their posting privileges limited or blocked.
I never thought that idea would be a big deal.
FN
Thanks ZF
You might answered some of my questions.
FN
My mistake!
I meant "Mauldin Economics"!
Leif,
Are you registered to Agora?
Thanks for the explanation !
It will get back there any way!
FN
Santorini - Greece
Don 't worry it's coming!
Ovidious is not very happy about that news!
I am!
FN
It's because they had a net loss of 6.3 millions of Dollars at their last quarter.
Due to the revers split!
But they have enough money for an other 2 years!
FN
http://www.howlifeworks.com/Article.aspx?Cat_URL=a&AG_URL=a&AG_ID=1358&CID=8077ia
Rare Undersea Discovery Could Extend Your Life by 10, 20 or 30 Years
Humans have made incredible health strides and are living longer lives than ever. Many of the maladies that struck down our ancestors have for the most part been completely eliminated – everything from tuberculosis, to polio to malaria.
Today, the biggest killers stem as much from our lifestyles as from microscopic bacteria and viruses. One of the worst of these is heart disease, and specifically high blood pressure. It’s a slow, but efficient killer that robs many people of what should be the last 10, 20 or 30 years of their lives.
Part of the reason that heart disease is so prevalent and intractable is that it often requires massive changes to one’s lifestyle— changes that are not easy to make. Everything from radically altering ones diet to implementing serious exercise routines. And while it’s never too late to start, people often realize the true danger only when it’s too late to make the changes and the damage is done.
Now, however, there may be a scientific breakthrough that could have an impact on high blood pressure comparable to penicillin’s ability treat infections or quinine’s effect on malaria.
Scientists are claiming that they have now isolated unusual ingredients in a rare seaweed discovered by fishermen off the coast of Korea that offer incredible health benefits—including the ability to restore blood pressure to normal levels.
Dr. Haengwoo Lee, a renowned biochemist living near Seattle, Washington conducted a massive 15 year, multimillion dollar clinical study on these two ingredients. The first is Seanol, an extremely rare seaweed extract from Ecklonia Cava that's proven to be 100 times more powerful than any land-based antioxidant. That's because it stays working in your body for 12 hours, compared to land-based antioxidants that work for 30 minutes.
"Its secret is its make-up of special polyphenol antioxidants that are a whopping 40% lipid (fat) soluble," Dr. Lee explains. "Unlike nearly all land-based antioxidants that are water soluble, Seanol's protective compounds can get into things like the fatty tissues of your brain and penetrate all three layers of your cells, including the outside, the oil-based cell membranes, and your DNA."
Indeed, Seanol is so powerful, it's the only FDA-approved Ecklonia Cava marine-algae extract in existence.
The second ingredient is Calamarine, a deep-sea omega-3 discovery that delivers 85% more DHA omega-3s to your heart, brain, joints, and eyes. It's known to combat everything from fatigue and poor memory, to vision problems, joint pain, mood swings and depression.
With that research in mind, Dr. Lee combined Seanol and Calamarine with a high dose of vitamin D to form Marine-D3, the newest supplement in the fight against age-related illnesses and high blood pressure.
According to the CDC, about 1 in 3 U.S. adults has high blood pressure, which increases the risk for heart disease and stroke, the two leading causes of death in the United States. Increasing your omega-3 intake can reduce high blood pressure, and because it's difficult to get enough omega-3s in foods like fish and nuts, many people turn to supplements.
Dr. Lee found that Calamarine delivers some of the greatest concentration of omega-3s known to science, and has been able to formulate it without any fishy burps or aftertaste. Combined with Seanol's ability to reduce body inflammation, as well as help cells get the nutrients they need to thrive, stay healthy and protected, Marine-D3 is able to boost a body's entire well being.
The makers of Marine-D3 are so confident that you'll see fast dramatic results from this product, that if you aren't happy after two full months, simply return the unused portion and they'll buy it back. They'll even give you ten dollars extra just for giving it an honest try! That kind of faith, combined with Dr. Lee's exhaustive research, shows that Marine-D3 really is a one-of-a-kind product.
Result of the last quarter:
http://www.hartfordbusiness.com/apps/pbcs.dll/article?AID=%2F20131118%2FNEWS01%2F131119942&template=printart
NanoViricides' losses increase as it develops flu drugs
11/18/2013
West Haven's NanoViricides Inc., a development-stage maker of anti-viral therapeutics, said its net loss for the quarter ended Sept. 30 was $6.3 million, more than triple its loss from the same quarter in 2012.
The company, which has six drugs in its development pipeline, reported that most of the additional loss was the result of a change in the fair market value of its derivatives. NanoViricides booked a $4.1 million loss in that category, up from $246,000 a year ago.
Despite the higher losses, the company said it has sufficient cash to support its operations for at least two years.
The company enacted a reverse split of its common stock in September, and its new stock began trading on the NYSE MKT exchange on Sept. 25.
Thank you for your warning!
I get your point. I join your website 4 years years ago.
Thanks to NNVC we created a friendship with many people on this board.
My intention was to create a club to cultivate our friendship.
Nothing else.
I will not mention this club on HB!
sincerely
Lorenzo Alias FORZANANO
AARON
The Email that you gave me is wrong. you need something between your 2 names like an undescore
What is it??
AARON
The 1st 2 names of your email are nor attached!
Is that OK?
I try that way!
Let me know
FN
I hope that we can change places and maybe meet in Hawaii with "SYOB"!
FN
I agree with that statment !
But no fighting about my opinions
I could be wrong!
FN
Yes
Only 1 year 1/2 dog = 10 years 1/2
So if you and I are not happy by then!
We can meet somewhere in Malibu
And getting really drunk!
FN
We don't need it in CA !
I went swimming yesterday !
After 10 rings you should be happy!
Yes, I was surprise when I saw the pictures that it would ready at the end of the year.
One of his feet could be the solution for your luck.
Hare close-upBefore Christianity in the British Isles, the hare, like the cat, was thought to be a witch in disguise. This witch could only be killed with a silver bullet.
Since rabbits and hares are born with eyes open, which is an erroneous notion, they supposedly had special powers over the evil eye.
It is believed to be unlucky to meet either a hare or a rabbit, one variant stating that a rabbit which crosses one's path in front is a good omen and one which crosses behind is a bad one. In some English counties it is considered unwise to shoot a black rabbit, as it may be an ancestral spirit returning in rabbit-form; in Suffolk it was believed that white rabbits were witches, which is was also unlucky to shoot. Rabbits and hares were never mentioned at sea, as they were considered ill-omened words, and to meet one on the way to see was a very bad omen.
Source: Vanessa's Pagan Place Folklore Page
An old custom is to say 'Rabbits' or 'White Rabbits' either once or three times on the first day of the month, as a good luck charm; it must be the first word said that morning, otherwise the charm is not potent.
Source: Vanessa's Pagan Place Folklore Page
: Because of the rabbit's ability to reproduce, the rabbit's foot also became a symbol of fertility. Rabbit's feet are also symbols of new life because of their prolificacy, they also were linked with darkness, witches and the devil because they live underground. By owning a rabbit's foot as a talisman, you would have vital connections with many powerful forces.
A left rabbit hind foot, carried in the left pocket after having been removed from a rabbit that was killed during a full moon by a cross-eyed person is truly lucky. The foot is considered a powerful charm against evil because the rabbit's strong hind legs touch the ground before its front legs. Ancient people thought this so remarkable that they ascribed magical powers to it.
A rabbit's foot is a well-known lucky charm in most English-speaking countries, said to ensure success in many fields. Actors may keep a rabbit's foot in their make-up cases for good luck, and will meet with misfortune if the foot is lost. In Wales an old belief is that a new-born child rubbed all over with a rabbit's foot will be lucky for life.
I though I red:
Bunny could be plus human.
Did you do it?
You are not there!
Great! See you on the other side!
oops!!
I didn't see that you did already post it!
Sorry!
FN
Hi Bizzy, did you received my invite?
http://www.jasonbondpicks.com/blog-posts/looking-for-a-long-term-triple-check-out-nanoviricides/
Looking For A Long-Term Triple; Check Out NanoViricides
Posted on November 14, 2013 at 9:32 pm in Blog Posts by Jason Bond
0 53 Google +0 1
On November 26, 2012 I published this report on NanoViricides (OTCBB:NNVC) calling it a solid 10-bagger opportunity. It’s been about a year and the company has not only listed on a national exchange but also advanced 209%. I encourage you to read my report from a year ago and then take a look at my latest research below. I strongly believe NanoViricides has the potential to trade well above $20, yes another 265%, for those looking for a long term idea.
NanoViricides – The Nano-Medicine Company That Thinks King Size
Deep down it is the ability of the biotech industry to find solutions for unmet medical needs that is driving the current upsurge in the sector. We have instances of companies with promising pipelines and no marketed drug valued at billion dollars and also companies with orphan drugs priced above $200,000 single handedly driving billion dollar valuations.
However, while some would say that it is a bubble waiting to burst, this writer is a firm believer that as long as investors apply their mind and choose bio stocks after due diligence, they can be reasonably assured of good, many times extraordinary, returns in the long run.
NanoViricides (AMEX:NNVC), is one such company, that has developed an innovative technology platform over which it can develop a number of drugs for several viruses.
NanoViricides
NanoViricides Inc is a development stage nano-biopharmaceutical company with a focus on life threatening viral infections. The company’s founder-president and also the principal investor, Anil R. Diwan, PhD, is an innovator-entrepreneur with a 25-year experience in the industry. Dr. Diwan developed TheraCour (therapeutic courier) Technology, which forms the basis of drugs being developed by NanoViricides.
To ensure quality corporate governance, the founder has made NanoViricides a public company with an independent Board of Directors.
Since the technology targets viruses, a brief introduction to the basics of viruses won’t be out of place here.
Viruses – basics
A virus is a pathogen which reproduces in the host’s body. It is an intelligent pathogen that, after invading, forces the host cell to reproduce thousands of copies of the original virus at an extremely rapid pace. These disease causing pathogens are one-hundredth the size of bacteria and as such, very elusive.
Antibiotics are ineffective against viruses. However, viruses provoke an immune response and are usually eliminated and normally the host cell develops lifetime immunity. Some viruses, such as herpes viruses, remain dormant for long periods causing persistent infections.
Science has discovered more than 5,000 species of viruses and each virus attacks a specific host cell or tissue and also has its own method of spreading – through moisture droplets while sneezing (influenza), through bodily fluids transferred through infected blood and during sex (HIV), the fecal-oral route (viral gastroenteritis) and blood sucking insects (dengue) and some by direct contact.
NanoViricides’ technology – a sought after new mechanism of action
A virus survives and propagates itself by attaching to the cell’s surface receptors, cell structures that exist for mediating between a chemical agent that acts on the nervous tissue and physiological response. The problem with viruses is that a virus keeps changing itself.
NanoViricides technology adopts an entirely new approach towards elimination of viruses. It is an approach that hasn’t been tried before. Drugs being developed by the company are not a standard anti-viral drug, nor vaccines or protease inhibitors. The technology does not target RNA or nucleotide mechanisms or something like that.
To counter the “intelligence” of viruses, the company is building “intelligent” nano-machines that use the virus’ own smartness to isolate, encapsulate and eliminate it. NanoViricides’ technology basically neutralizes the virus by tricking it to bind to the drug developed by it instead of the receptors on the cell surface. A compact but flexible mass envelops the virus, leading to loss of proteins it needs for survival.
Attacking the virus directly provides the safety, as well as the confidence that if preclinical studies of a drug succeed in animal models it will succeed in humans as well.
TheraCour technology carries two all-encompassing patents and eighteen applications for patents are pending in different countries. Keeping in mind the growing trend of countries denying patent protection, to ensure full protection the company plans to get as much as 100 patents.
Pipeline update – fighting the virus’s ability to develop drug resistance
Dr. Diwan, in a presentation, explained that resistance to drugs developed by NanoViricides is futile because they attack the virus directly. No matter whichever virus type, A, B or C or a new strain is causing influenza, the same drug would work to eliminate the virus. The quantity or sensitivity may vary, but the drug will be the same.
The company has six drugs in pipeline for five viruses, two of them in relatively advanced development stage. In early September, 2013, the company announced that its oral anti-influenza drug candidates, FluCide, demonstrated significant protection from the disease in animal models and also superior to oral TamiFlu of Roche (OTCBB: RHHBY)
Later, on October 7, 2013, the company announced that it had initiated a non-GLP toxicology evaluation of its optimized injectible FluCide after holding a pre-IND meeting with the FDA, a significant step in furtherance of the development process of the drug.
Earlier, in August 2013, the FDA granted orphan drug status to DengueCide, the company’s candidate for treatment of dengue and dengue hemorrhagic fever.
Summary
While injectible FluCide is meant for hospitalized patients with influenza, its oral version, if approved, will be the first ever effective oral anti-flu nano-medicine. The company is also studying the drug for immuno-compromised patients and might get an orphan drug status for that indication.
NanoViricides is the first company in the world that is developing oral nano-medicines. Nano medicine is being being promoted aggressively by the NCI but all products in development are injectibles for the simple reason that nano drugs breakdown easily in the stomach and by pancreatic fluids. NanoViricides has been able to develop a mechanism that allows nano-medicine to be delivered orally and still be effective. This opens up a very large market for the company. The company estimates the market size in the range of $4-7 billion for an oral anti-influenza nano medicine and for the full range of its pipeline drugs to be more than $40 billion.
At the same time, the fact is that the company’s entire pipeline is still in its nascent development stage and has yet to proceed towards human testing.
Investor viewpoint
Investment in biotech is all about potential and ability to carry on the development process. NanoViricides is a technology based biotech. It is a platform technology and there is no end to the number of drugs it can develop as only a small invention is required for working on a new drug for another virus.
NanoViricides provides an opportunity for investors with a long investment horizon – they might have to wait for a few years but the gains can be phenomenal.
- See more at: http://www.jasonbondpicks.com/blog-posts/looking-for-a-long-term-triple-check-out-nanoviricides/#sthash.JmrMdVHh.dpuf
nanopatent
Well said!
Hi Nick
Welcome to the board! Just a quick comment on your uncle.
I have great respect for him. He is very open and very honest.
NNVC is very lucky to have him as CEO.
I hope to meet you one of these days.
FN
NanoViricides Inc (NNVC): This Virtually Unknown Stock Could Double Traders’ Money
By PROFITABLETRADING in News
Published: September 5, 2013 at 10:41 am
http://www.insidermonkey.com/blog/nanoviricides-inc-nnvc-this-virtually-unknown-stock-could-double-traders-money-237160/?singlepage=1
In a globally-connected world, viruses can spread quickly. From influenza to dengue fever to herpes to HIV, viral contagions can spread at an alarming pace. Trouble is, doctors researching these viruses, known as virologists, have found it quite difficult to identify permanent cures. For example, even though doctors completely understand how the flu virus works, millions of people still come down with a flu bug every year. And in some instances, the flu can have fatal consequences.
But little-known NanoViricides Inc (OTCBB:NNVC) may have "cracked the code" when it comes to viruses. The company still has a lot to prove, as is the case with any young biotech stock that trades for around $1. But it appears to be making progress, and if it can deliver on at least one of its several drugs in development, then the upside could be significant.
Though the company has been around since 2005, the past year has been quite eventful, and NanoViricides Inc (OTCBB:NNVC) is seeing increasing trading volume and a rising share price.
Here's a quick timeline of NanoViricides Inc (OTCBB:NNVC)' recent progress:
-- November 2012: The company hires Bioanalytical Systems (NASDAQ: BASI) to conduct safety studies for its influenza drug, FluCide. The design of the study had previously been approved by the FDA. In late 2012, the company also identified a facility and management group that will oversee the construction of production lines that will provide a high volume of drugs to be used in clinical trials. The facility is expected to be ready by late 2013 or early 2014.
-- January 2013: Early pre-clinical trials produce efficacy results that are stronger than Roche Holding's (OTC: RHHBY) Tamiflu, the current most popular flu vaccine available for sale.
-- February 2013: The company completes a $6 million capital raise, and along with $5 million raised in 2012, said it believes it has enough cash on hand to fund operations through the end of 2014 while pursuing initial human clinical trials.
-- June 2013: The company files for orphan drug status with the FDA for its DengueCide drug to treat dengue fever and receives that designation from the FDA in mid-August. A similar application with the European Medicines Agency (EMA) is filed in July, and EMA approval is granted in September.
-- June 2013: The Lovelace Respiratory Research Institute, a biomedical research organization with 1,200 employees and 150 PhDs, agrees to conduct clinical studies for NanoViricides Inc (OTCBB:NNVC)' flu drug, as well as a drug that is aimed at the MERS virus (Middle East respiratory syndrome coronavirus).
Though NanoViricides Inc (OTCBB:NNVC) believes that a wide range of viruses can be treated with its biotechnology, influenza and dengue fever clearly stand out as key areas of focus for the company in the near term.
What kind of market opportunities are we looking at? Well, Tamiflu has proven to be popular for treating influenza, with a potential annual revenue opportunity exceeding $3 billion, according to Influmedix.com.
There is no current cure for dengue fever, nor can we glean a market size for a drug that treats it. But the World Health Organization believes there may be 50 million to 100 million dengue infections worldwide every year.
To be sure, this small company also carries considerable risk. Many drugs that appear quite promising in small-scale tests fail to deliver solid safety and efficacy data as clinical trials grow larger. Indeed, the vast majority of early stage drugs fail, and NNVC's stock price would plunge sharply if that were to happen.
Moreover, a steady stream of capital infusions over the years has caused the share count to swell to 163 million. Investors should assume that the company needs to issue at least 40 million or 50 million more shares in coming years to further fund clinical trials. The company could also choose to sign a marketing deal with a large drug company, which would likely provide an equity infusion in exchange for sales rights, eliminating the need for further dilution.
Lastly, investors are waiting for a financial report regarding NanoViricides' fiscal fourth quarter, which ended in June. The company's 10-K for fiscal 2012 was filed in mid-October, so investors will presumably receive this year's 10-K on or before that date. When the 10-K is filed, investors should read it very closely to identify any possible concerns regarding the current development efforts and cash levels.
While it's virtually impossible to develop a specific target price for NNVC, we can make some broad assumptions. First, let's assume that the number of shares outstanding eventually rises to 200 million. Second, let's assume that the company is targeting an annual revenue opportunity of $500 million. Third, let's assume that shares are eventually valued at three times revenue, or $1.5 billion. Lastly, let's assume that NanoViricides has only a 33% chance of success, so reduce that number back down to $500 million.
That equates to $2.50 a share, or about 100% upside from current levels. And if the company successfully brings its key drugs to market, then the ultimate $1.5 billion market value represents a move in the stock up to $7.50, a nearly 500% gain.
AZ officials keep close eye on mosquito capable of transmitting Yellow Fever
http://www.kpho.com/story/23733412/az-officials-keep-close-on-on-mosqito-capable-of-transmitting-yellow-fever
PHOENIX (CBS5) -
Aedes Aegypt mosquitos have been in Arizona for about the past decade.
However, they're new to California, and Maricopa County Environmental Services wants to make sure no dangerous diseases start spreading throughout the population.
"Because they like to feed on humans, (Aedes Aegypt) mosquitos tend to spread diseases that go back and forth from humans like Yellow Fever," said John Townsend, the Vector Control Division Manager for Maricopa County Environmental Services.
The small pests are known commonly as "ankle biters" since they're extremely small and usually focus their attack on those areas. ??They have been known to be in Arizona for the past 10 years. California has began to spot them in some northern counties, and now officials are trying to eradicate them before they spread.
In Arizona, officials are doing this same.
"This is a carbon monoxide trap," explained Townsend, pointing to a device made out of a thermos and fan. ??"Mosquitos comes in, and there is a fan in here. As they fly around, they get sucked in here and pushed into the bag," he continued.
Then the bugs are tested in a lab to see if they are positive for any type of disease.
"Not every mosquito out there is carrying some kind of disease, but there is a possibility," said Townsend.
Though it's unlikely these mosquitos will carry diseases like Yellow Fever, if someone who travels overseas contracts the illness, it could spread easily by the tiny bugs.
Townsend says the best way to prevent the spread of these mosquitoes is to eliminate even small amounts of water from your property.
Bizzy
Just did !
We are becoming a nice group!
12 people so far!
FN
OK You should get it now!
If not send me back your email all attached
Here is my email: lorenzo_manaigo@hotmail.com
Aaron
Did you received my invite?
Global Warning!!!
Nanoviricides has a lot of works to do to save the planet!!
FN
Agreed with BF!
leif!
It's your turn to join NANO CLUB!
The best club on Facebook !!
FN
Ask Nanotoday!
He is an expert!
Yes, that the difference between us and the Roman!